This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Franco Lori, MD; Heiko Jessen, MD
Berlin, Germany

Andrea Foli, MD; Julianna Lisziewicz, PhD
Research Institute for Genetic and Human Therapy Gaithersburg, Md

Policlinico S. Matteo
Pavia, Italy

JAMA. 1997;277(18):1437-1438.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The use of hydroxyurea has been brought rapidly from laboratory studies to clinical implementation. After our initial demonstration of the potential use of hydroxyurea to inhibit human immunodeficiency virus (HIV)-1 replication,¹ other laboratories have shown that hydroxyurea and didanosine appear to be a powerful combination and lead to synergistic effects.²

In this study, 6 consecutive patients (Table) were treated with a combination of hydroxyurea (250-mg dose, 4 times per day) and didanosine (200-mg dose, 2 times per day). The group represented a heterogeneous population. Three patients had acquired immunodeficiency syndrome (AIDS), and 1 (patient 4) was enrolled following an episode of acute mononucleosis-like HIV syndrome 8 weeks after documented seroconversion.

The response to treatment revealed a consistent pattern independent of previous exposure to antiretroviral treatment and disease stage. An initial sharp decrease in viremia (average, 84.5%) was observed in all patients 2 to 6 weeks after . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?